Vividion Therapeutics

Vividion Therapeutics' Mission and Vision

Vividion Therapeutics is dedicated to developing therapies for patients with critical unmet needs across multiple therapeutic areas. By combining decades of research with unprecedented scientific know-how, Vividion aims to deliver groundbreaking treatments for difficult-to-target diseases. The company's mission is to transform the landscape of drug discovery and development by focusing on traditionally undruggable targets, specifically in the fields of oncology and immunology.

Vividion Therapeutics' Chemoproteomic Platform

Vividion Therapeutics utilizes a proprietary chemoproteomic platform to advance its pipeline of highly selective small molecule therapeutics. This innovative platform enables the identification of previously unknown functional pockets on well-validated protein targets, making it possible to develop drugs for traditionally undruggable targets. The technology has been instrumental in the discovery and optimization of lead programs targeting NRF2, STAT3, and WRN, as well as several undisclosed programs in the lead optimization phase.

Vividion Therapeutics' Clinical Trials and Research

Vividion Therapeutics has made significant strides in clinical research, including publishing a landmark Nature paper on a clinical-stage covalent allosteric inhibitor of Werner Helicase (WRN) in collaboration with Roche. The company has initiated a Phase I clinical trial for VVD-130850, an investigational oral small molecule inhibitor of STAT3, aimed at treating advanced solid and hematologic tumors. Additionally, VVD-133214 (RO7589831) is being evaluated in a Roche-sponsored Phase 1 first-in-human trial for MSI-high cancers.

Vividion Therapeutics' Acquisition by Bayer AG

In August 2021, Vividion Therapeutics was acquired by Bayer AG, becoming a wholly owned and independently operated subsidiary. This acquisition allows Vividion to preserve its innovative and entrepreneurial culture while benefiting from Bayer's extensive expertise and resources. Operating at arm's length from its parent company, Vividion continues to focus on its core mission of advancing small molecule therapeutics for oncology and immunology.

Vividion Therapeutics' Key Programs and Pipeline

Vividion Therapeutics has a diversified pipeline of small molecule therapeutics targeting key proteins in oncology and immunology. The lead programs include inhibitors targeting NRF2, STAT3, and WRN, aimed at addressing critical unmet needs in cancer treatment. The company is also advancing several undisclosed programs that are in the lead optimization phase, showcasing its commitment to expanding the frontiers of drug discovery through its proprietary chemoproteomic platform.